Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 301, Issue 4, 2011, Pages

  Pyle, Louise C ^a   Ehrhardt, Annette ^b   Mitchell, Lisa High ^a,c   Fan, Lijuan ^a   Ren, Aixia ^d   Naren, Anjaparavanda P ^d   Li, Yao ^a   Clancy, J P ^a   Bolger, Graeme B ^a,c   Sorscher, Eric J ^a,b,c   Rowe, Steven M ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cystic fibrosis; Potentiators; Protein kinase A; Short circuit current

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; CYCLIC AMP; FORSKOLIN; IVACAFTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UCCF 152; UNCLASSIFIED DRUG; VRT 532;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; ENZYME ASSAY; FISCHER 344 RAT; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THYROID CELL; WILD TYPE;

AMINOPHENOLS; ANIMALS; BLOTTING, WESTERN; CELL LINE; CERCOPITHECUS AETHIOPS; CRESOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIFFUSION CHAMBERS, CULTURE; DIMERIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORSKOLIN; GENE EXPRESSION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION CHANNEL GATING; ION TRANSPORT; LENTIVIRUS; MEMBRANE TRANSPORT MODULATORS; MICE; MUTATION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PYRAZOLES; QUINOLONES; RETROVIRIDAE; TRANSDUCTION, GENETIC;

EID: 80053353499     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00465.2010     Document Type: Article

References (49)

1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991-2003, 2010.
2. Al-Nakkash L, Hu S, Li M, Hwang TC. A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs. J Pharmacol Exp Ther 296: 464-472, 2001.
3. Baker JM, Hudson RP, Kanelis V, Choy WY, Thibodeau PH, Thomas PJ, Forman-Kay JD. CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat Struct Mol Biol 14: 738-745, 2007.
4. Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, Conti M, Stutts MJ, Milgram SL. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 280: 7997-8003, 2005.
5. - airway epithelial monolayers. J Physiol 569: 601-615, 2005.
6. Bronsveld I, Mekus F, Bijman J, Ballmann M, de Jonge HR, Laabs U, Halley DJ, Ellemunter H, Mastella G, Thomas S, Veeze HJ, Tummler B. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 108: 1705-1715, 2001.
7. Caci E, Folli C, Zegarra-Moran O, Ma T, Springsteel MF, Sammelson RE, Nantz MH, Kurth MJ, Verkman AS, Galietta LJ. CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol Lung Cell Mol Physiol 285: L180- L188, 2003.
8. Chappe V, Irvine T, Liao J, Evagelidis A, Hanrahan JW. Phosphorylation of CFTR by PKA promotes binding of the regulatory domain. EMBO J 24: 2730-2740, 2005.
9. - transport by cystic fibrosis transmembrane conductance regulator. JOP 2: 243-246, 2001.
10. Csanady L, Nairn AC, Gadsby DC. Thermodynamics of CFTR channel gating: a spreading conformational change initiates an irreversible gating cycle. J Gen Physiol 128: 523-533, 2006.
11. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, Lazdunski M. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354: 526-528, 1991.
12. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
13. Devor DC, Bridges RJ, Pilewski JM. Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. Am J Physiol Cell Physiol 279: C461-C479, 2000.
14. Ehrhardt A, David MD, Ehrhardt GR, Schrader JW. Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. Mol Cell Biol 24: 6311-6323, 2004.
15. Ehrhardt C, Collnot EM, Baldes C, Becker U, Laue M, Kim KJ, Lehr CM. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o. Cell Tissue Res 323: 405-415, 2006.
16. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440: 477-483, 2006.
17. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for highthroughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 281: C1734-C1742, 2001.
18. Howell LD, Borchardt R, Kole J, Kaz AM, Randak C, Cohn JA. Protein kinase A regulates ATP hydrolysis and dimerization by a CFTR (cystic fibrosis transmembrane conductance regulator) domain. Biochem J 378: 151-159, 2004.
19. Johannes FJ, Prestle J, Dieterich S, Oberhagemann P, Link G, Pfizenmaier K. Characterization of activators and inhibitors of protein kinase C mu. Eur J Biochem 227: 303-307, 1995.
20. Lewis HA, Buchanan SG, Burley SK, Conners K, Dickey M, Dorwart M, Fowler R, Gao X, Guggino WB, Hendrickson WA, Hunt JF, Kearins MC, Lorimer D, Maloney PC, Post KW, Rajashankar KR, Rutter ME, Sauder JM, Shriver S, Thibodeau PH, Thomas PJ, Zhang M, Zhao X, Emtage S. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J 23: 282-293, 2004.
21. Ma J, Zhao J, Drumm ML, Xie J, Davis PB. Function of the R domain in the cystic fibrosis transmembrane conductance regulator chloride channel. J Biol Chem 272: 28133-28141, 1997.
22. Mense M, Vergani P, White DM, Altberg G, Nairn AC, Gadsby DC. In vivo phosphorylation of CFTR promotes formation of a nucleotidebinding domain heterodimer. EMBO J 25: 4728-4739, 2006.
23. Pasyk S, Li C, Ramjeesingh M, Bear CE. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease. Biochem J 418: 185-190, 2009.
24. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS. Small-molecule correctors of defective DeltaF508- CFTR cellular processing identified by high-throughput screening. J Clin Invest 115: 2564-2571, 2005.
25. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, Nantz MH, Kurth MJ, Galietta LJ, Verkman AS. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 67: 1797-1807, 2005.
26. Pyle LC, Fulton JC, Sloane PA, Backer K, Mazur M, Prasain J, Barnes S, Clancy JP, Rowe SM. Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of DeltaF508 cystic fibrosis transmembrane conductance regulator rescue. Am J Respir Cell Mol Biol 43: 607-616, 2009.
27. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [published erratum appears in Science 1989 Sep 29, 245(4925):1437]. Science 245: 1066-1073, 1989.
28. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 352: 1992-2001, 2005.
29. Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 23: 268-278, 2010.
30. Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol 37: 347-356, 2007.
31. Sammelson RE, Ma T, Galietta LJ, Verkman AS, Kurth MJ. 3-(2- Benzyloxyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bioorg Med Chem Lett 13: 2509-2512, 2003.
32. Scott-Ward TS, Cai Z, Dawson ES, Doherty A, Da Paula AC, Davidson H, Porteous DJ, Wainwright BJ, Amaral MD, Sheppard DN, Boyd AC. Chimeric constructs endow the human CFTR Cl channel with the gating behavior of murine CFTR. Proc Natl Acad Sci USA 104: 16365-16370, 2007.
33. Seavilleklein G, Amer N, Evagelidis A, Chappe F, Irvine T, Hanrahan JW, Chappe V. PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR. Am J Physiol Cell Physiol 295: C1366-C1375, 2008.
34. Sermet-Gaudelus I, Vallee B, Urbin I, Torossi T, Marianovski R, Fajac A, Feuillet MN, Bresson JL, Lenoir G, Bernaudin JF, Edelman A. Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous (Delta)F508 mutation. Pediatr Res 52: 628-635, 2002.
35. Serohijos AW, Hegedus T, Aleksandrov AA, He L, Cui L, Dokholyan NV, Riordan JR. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci USA 105: 3256-3261, 2008.
36. Springsteel MF, Galietta LJ, Ma T, By K, Berger GO, Yang H, Dicus CW, Choung W, Quan C, Shelat AA, Guy RK, Verkman AS, Kurth MJ, Nantz MH. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 11: 4113-4120, 2003.
37. Thelin WR, Kesimer M, Tarran R, Kreda SM, Grubb BR, Sheehan JK, Stutts MJ, Milgram SL. The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A. J Biol Chem 280: 41512-41520, 2005.
38. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106: 18825-18830, 2009.
39. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117-L1130, 2006.
40. Vastiau A, Cao L, Jaspers M, Owsianik G, Janssens V, Cuppens H, Goris J, Nilius B, Cassiman JJ. Interaction of the protein phosphatase 2A with the regulatory domain of the cystic fibrosis transmembrane conductance regulator channel. FEBS Lett 579: 3392-3396, 2005.
41. Wang F, Zeltwanger S, Hu S, Hwang TC. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 524: 637-648, 2000.
42. Wang F, Zeltwanger S, Yang IC, Nairn AC, Hwang TC. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 111: 477-490, 1998.
43. Wang Y, Bartlett MC, Loo TW, Clarke DM. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70: 297-302, 2006.
44. Wang Y, Loo TW, Bartlett MC, Clarke DM. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem 282: 33247-33251, 2007.
45. Wang Y, Loo TW, Bartlett MC, Clarke DM. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 71: 751-758, 2007.
46. Wellhauser L, Chiaw PK, Pasyk S, Li C, Ramjeesingh M, Bear CE. A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol 75: 1430-1438, 2009.
47. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73: 1251-1254, 1993.
48. Winter MC, Welsh MJ. Stimulation of CFTR activity by its phosphorylated R domain. Nature 389: 294-296, 1997.
49. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, Galietta LJ, Verkman AS. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 278: 35079-35085, 2003.